Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence
Autore:
Poon, RTP; Ngan, H; Lo, CM; Liu, CL; Fan, ST; Wong, J;
Indirizzi:
Univ Hong Kong, Queen Mary Hosp, Med Ctr, Dept Surg & Diagnost Radiol,Ctr Liver Dis, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong Hong Kong Hong Kong Peoples R China Kong, Peoples R China
Titolo Testata:
JOURNAL OF SURGICAL ONCOLOGY
fascicolo: 2, volume: 73, anno: 2000,
pagine: 109 - 114
SICI:
0022-4790(200002)73:2<109:TCFIHC>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSCATHETER ARTERIAL EMBOLIZATION; PERCUTANEOUS ETHANOL INJECTION; POSTOPERATIVE RECURRENCE; OILY CHEMOEMBOLIZATION; PROGNOSTIC FACTORS; ETHIODIZED OIL; MANAGEMENT; RESECTION; THERAPY; HEPATECTOMY;
Keywords:
hepatocellular carcinoma; inoperable; recurrence; transarterial chemoembolization;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Poon, RTP Queen Mary Hosp, Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, PeoplesR China Queen Mary Hosp 102 Pokfulam Rd Hong Kong Hong Kong Peoples R China
Citazione:
R.T.P. Poon et al., "Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence", J SURG ONC, 73(2), 2000, pp. 109-114

Abstract

Background and Objectives: The role of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) has remained controversial, and its efficacy for postresection intrahepatic recurrence has not been fully assessed. A study was performed to evaluate the treatment results andprognostic factors of TACE treatment in these patients. Methods: Clinicopathologic data and treatment results of 384 patients withinoperable HCC and 100 patients with postresection recurrent HCC treated with TACE were collected prospectively and analyzed. Results: TACE was associated with an overall treatment morbidity rate of 23% (112/484) and mortality rate of 4.3% (21/484). A particularly high mortality rate of 20% (9/45) was observed among patients with tumors > 10 cm andpretreatment serum albumin level less than or equal to 35 g/L. The overall1-year, 3-year, and 5-year survival rates from the time of first TACE treatment were 49%, 23%, and 17% respectively. Tumor size less than or equal to10 cm and serum albumin level > 35 g/L were independent favorable prognostic factors. TACE in patients with postresection recurrent HCC was associated with less morbidity, mortality, and a better survival outcome compared with patients with primary inoperable HCC, but this was largely related to smaller tumor size and better liver function in the former group at the time of TACE treatment. Conclusions: TACE in patients with inoperable HCC was associated with significant morbidity and mortality, and the survival benefit was limited. Better patient selection in terms of tumor size and liver function may improve treatment results. Patients who have a tumor > 10 cm and poor liver function (serum albumin less than or equal to 35 g/L) may not be suitable candidates for TACE treatment. (C) 2000 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 15:12:57